Venrock Adviser, LLC
NEW YORK, NY · CIK 1615982 · 13F filing filed 2021-08-13
SEC-registered investment adviser since 2014 · limited liability company
- Assets managed$4.5bn
- Staff11 · 11 in investment roles
- Main clients (by assets)Private funds 100%
- Private funds7 (1 hedge) · $4.5bn gross assets
- Form ADV · 2026-04-28SEC adviser record
- Legal entityVENROCK ADVISER, LLC (US)
- Kindhedge funds, private equity
- Others nearbyNew York, NY, Palo Alto, CA
As an employer
- Offices in1 country
- Private fundshedge 1, private equity 6
Where they work
Offices
From Form ADV: the main office and the other offices where it does advisory work (at most the 25 largest), with the people doing investment work at each. “About” is worked out: the firm's investment staff less its other offices. Each city links to the other managers there.
| City | People |
|---|---|
| New York, NY (main office)United States | about 11 |
| Palo Alto, CAUnited States |
Map: places from GeoNames (CC BY 4.0), outlines from Natural Earth.
$824.4m
reported value
-10.6% vs Q1 2021
29positions
67.7%in top 10
9 new
2 added
6 reduced
8 sold out
vs Q1 2021
Holdings, Q2 2021
The small lines show how much was held over the last 4 quarters (adjusted for stock splits).
| Security | Value | Change |
|---|---|---|
| INSTIL BIO INC COM | $132.6m16.09% | Unchanged |
| ACLARIS THERAPEUTICS INC ACRS | $80.1m9.72% | Added +843.4k |
| VISTAGEN THERAPEUTICS INC VTGN | $50.5m6.13% | Reduced -255.3k |
| GRAPHITE BIO INC GRPH | $49.6m6.01% | New |
| MARINUS PHARMACEUTICALS INC MRNS | $47.4m5.75% | Unchanged |
| RELMADA THERAPEUTICS INC RLMD | $44.4m5.39% | Added +534.5k |
| OLEMA PHARMACEUTICALS INC OLMA | $43.0m5.21% | Unchanged |
| CELLDEX THERAPEUTICS INC NEW CLDX | $41.5m5.03% | Unchanged |
| ALTIMMUNE INC ALT | $34.5m4.18% | Unchanged |
| KINNATE BIOPHARMA INC KNTE | $34.3m4.16% | Unchanged |
| GH RESEARCH PLC GHRS | $27.7m3.36% | New |
| CULLINAN THERAPEUTICS INC CGEM | $25.1m3.05% | Reduced -200.0k |
| CENTESSA PHARMACEUTICALS PLC SPONSORED ADS | $25.0m3.04% | New |
| PROVENTION BIO INC PRVB | $24.5m2.97% | New |
| TRILLIUM THERAPEUTICS INC TR | $19.4m2.36% | Reduced -2.0m |
| ESSA PHARMA INC EPI | $17.9m2.17% | Unchanged |
| CVRX INC CVRX | $17.7m2.15% | New |
| PHARVARIS N V PHVS | $16.8m2.04% | Unchanged |
| ATHIRA PHARMA INC COM | $15.2m1.84% | Reduced -206.6k |
| RAPT THERAPEUTICS INC COM | $12.4m1.51% | New |
| KURA ONCOLOGY INC KURA | $12.0m1.45% | Unchanged |
| KEROS THERAPEUTICS INC KROS | $11.6m1.40% | Reduced -100.0k |
| COGENT BIOSCIENCES INC COGT | $8.8m1.07% | Unchanged |
| ALIGOS THERAPEUTICS INC COM | $8.3m1.01% | Unchanged |
| AKOYA BIOSCIENCES INC AKYA | $7.7m0.94% | New |
| HARPOON THERAPEUTICS INC COM | $7.1m0.86% | New |
| CATABASIS PHARMACEUTICALS IN CATB | $6.8m0.83% | New |
| ADICET BIO INC COM | $1.9m0.23% | Reduced -816.3k |
| VIRIDIAN THERAPEUTICS INC VRDN | $357.0k0.04% | Unchanged |
Sold out since Q1 2021
| Security | Value then |
|---|---|
| CONSTELLATION PHARMCETICLS I CNST | $94.0m4.0m shares |
| SYNDAX PHARMACEUTICALS INC SNDX | $13.2m591.8k shares |
| APTOSE BIOSCIENCES INC | $9.6m1.6m shares |
| EYEPOINT PHARMACEUTICALS INC EYPT | $7.1m700.0k shares |
| BCTG ACQUISITION CORP | $5.6m500.0k shares |
| METACRINE INC | $4.2m680.0k shares |
| ARS PHARMACEUTICALS INC SPRY | $3.7m85.0k shares |
| TAYSHA GENE THERAPIES INC TSHA | $2.4m120.6k shares |